Anti-interleukin 1 immunomodulatory agents targeting the inflammasome have been shown to reduce cardiovascular events in coronary atherosclerosis patients with abnormal high sensitivity CRP [36], to improve left ventricular remodelling in those with ST elevation myocardial infarction [37] and to treat patients with idiopathic recurrent acute pericarditis (IRAP) [38,39]. The gene discussed is CRP; the disease is coronary atherosclerosis.